Every strategy picks one stock after each US market close. The next morning $100 goes into it at the opening price, on paper, and it is never sold. Here is every pick since the start, winners and losers, next to the same money in the S&P 500.
Sign up free to see each strategy’s pick every day, with the reason for it in plain words. This page stays public either way.
The rule. The stocks with the highest return over the last 6 months.
Deeper drops than the core strategies: −45% in the last five years of the backtest
To the close on 4 Nov 2026. A paper portfolio: $100 at every market open, nothing sold.
Winning streak, the same money in the S&P 500, and the money put in
Past performance does not guarantee future results. How the strategies work
16 of 16 picks bought so far are ahead of the S&P 500 over the same days. 16 are up and 0 are down.
Best: MRNA ▲ +38.2%, picked 23 Oct 2026. Worst: MRNA ▲ +6.7%, picked 20 Oct 2026.
1 pick buys at the next open.
Before a strategy goes live, its rule is run on past prices. This is that test: $100 every trading day from 3 Nov 2016 to 3 Nov 2026, next to the same money in the S&P 500. Nobody invested this money. Expect live results to be lower.
| Period | Return a year | S&P 500 | Put in | Grew to | S&P 500 | Worst drop | S&P 500 |
|---|---|---|---|---|---|---|---|
| 10 years 2016 to 2026 | ▲ 20.7% | 15.3% | $251,200 | $740,859 | $554,539 | −38% | −34% |
| First 5 years 2016 to 2021 | ▲ 24.6% | 20.8% | $125,800 | $228,532 |
| Picked | Stock | Bought at | Since buying | S&P 500, same days | Ahead or behind |
|---|---|---|---|---|---|
| 4 Nov 2026 | MRNA Moderna, Inc. | Buys at the next open | |||
| 3 Nov 2026 | MRNA Moderna, Inc. | $235.00 open, 4 Nov | ▲ +9.9% | ▲ +0.5% | ▲ 9.4 pts ahead |
| 2 Nov 2026 | MRNA Moderna, Inc. | $222.02 open, 3 Nov | ▲ +16.4% | ▲ +1.9% | ▲ 14.5 pts ahead |
| 30 Oct 2026 | MRNA Moderna, Inc. | $224.16 open, 2 Nov | ▲ +15.3% | ▲ +1.0% | ▲ 14.3 pts ahead |
| 29 Oct 2026 | MRNA Moderna, Inc. | $220.53 open, 30 Oct | ▲ +17.2% | ▲ +0.7% | ▲ 16.5 pts ahead |
| 28 Oct 2026 | MRNA Moderna, Inc. | $216.43 open, 29 Oct | ▲ +19.4% | ▼ −0.3% | ▲ 19.6 pts ahead |
| 27 Oct 2026 | MRNA Moderna, Inc. | $204.00 open, 28 Oct | ▲ +26.7% | ▼ −0.6% | ▲ 27.3 pts ahead |
| 26 Oct 2026 | MRNA Moderna, Inc. | $192.23 open, 27 Oct | ▲ +34.4% | ▼ −0.1% | ▲ 34.5 pts ahead |
| 23 Oct 2026 | MRNA Moderna, Inc. | $186.90 open, 26 Oct | ▲ +38.2% | ▲ +0.6% | ▲ 37.6 pts ahead |
| 22 Oct 2026 | MRNA Moderna, Inc. | $196.69 open, 23 Oct | ▲ +31.4% | ▲ +0.9% | ▲ 30.5 pts ahead |
| 21 Oct 2026 | MRNA Moderna, Inc. | $240.13 open, 22 Oct | ▲ +7.6% | ▲ +0.1% | ▲ 7.5 pts ahead |
| 20 Oct 2026 | MRNA Moderna, Inc. | $242.20 open, 21 Oct | ▲ +6.7% | ▼ −0.6% | ▲ 7.2 pts ahead |
| 19 Oct 2026 | MRNA Moderna, Inc. | $226.03 open, 20 Oct | ▲ +14.3% | ▲ +0.1% | ▲ 14.2 pts ahead |
| 16 Oct 2026 | MRNA Moderna, Inc. | $217.27 open, 19 Oct | ▲ +18.9% | ▼ −0.1% | ▲ 19.0 pts ahead |
| 15 Oct 2026 | MRNA Moderna, Inc. | $235.00 open, 16 Oct | ▲ +9.9% | ▼ −0.8% | ▲ 10.8 pts ahead |
| 14 Oct 2026 | MRNA Moderna, Inc. | $225.48 open, 15 Oct | ▲ +14.6% | ▲ +0.1% | ▲ 14.5 pts ahead |
| 13 Oct 2026 | MRNA Moderna, Inc. | $217.49 open, 14 Oct | ▲ +18.8% | ▼ −1.0% | ▲ 19.8 pts ahead |
Each return runs from the opening price the pick was bought at to the close on 4 Nov 2026, dividends included. The S&P 500 figure is SPY, a fund that tracks the index, bought at the same open. Ahead or behind is the gap between the two in percentage points (pts): a pick up 5% while the index is up 3% is 2 pts ahead.
| $209,142 |
| −38% |
| −34% |
| Last 5 years 2021 to 2026 | ▲ 23.6% | 17.3% | $125,400 | $222,907 | $191,574 | −35% | −25% |
|---|
How the test was run: each day was ranked only on prices up to that day’s close, among the companies that were in the S&P 500 on that day, including ones that have since left. The pick was bought at the next day’s opening price and never sold. Dividends are included, 0.05% comes off every buy for trading costs, and no more than 10% went into one stock or 30% into one sector. “Return a year” is the yearly rate the money earned, counting when each $100 went in. “Worst drop” is the biggest fall from a high point along the way. The two five-year tests each start again from nothing. Past performance, tested or live, does not guarantee future results.